cIMPACT-Now Update 4 highlights the importance of integrated diagnostics in assessing WHO grade II IDH wild-type/H3-wild-type diffuse gliomas, particularly those with MYB or MYBL1 rearrangements.148 These mutations are associated with a favorable prognosis, with gliomas harboring MYB or MYBL1 alterations demonstrating prolonged disease stability and high OS rates. This evidence concerns the gene MYB and central nervous system cancer.